COVID Vaccine BLA Review ‘Sprint’: Elevating Marks Role Could Have Drawbacks
US FDA veterans offered varying opinions as to the benefits and risks of the CBER director taking on a more hands-on role in reviewing Pfizer’s COVID-19 vaccine. The move was called unusual, but not inappropriate; some said it should be monitored closely to ensure review staff’s judgements are not pushed aside.
You may also be interested in...
US FDA’s Top Two Vaccine Officials Announce Surprise Retirements
Departures of Marion Gruber and Philip Krause may stem from White House and CDC actions related to the COVID-19 vaccines.
World No. 1 Or US No. 3? Global Access May Factor Into US Booster Shot Decision
A third shot of COVID-19 vaccine may be recommended for Americans soon, but the CDC says the best defense against the pandemic in the US includes ensuring the entire world gets the primary series.
When Should COVID Vaccines Get Full Approval? US FDA Squeezed By ‘Too Fast’ And ‘Too Slow’ Camps
Some experts argue full FDA approval will help boost vaccination rates that are waning, but others want the agency to mandate studies in special populations and gather other data before making a final decision.